The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient.
Industry Buzz Growing Rapidly Around MINDCURE’s iSTRYM
Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE's iSTRYM digital therapeutics platform is the first-mover in the industry.
Compass study result validates industry's hope to find alternative treatments for mental health
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues.
Psychedelics-Assisted Therapy: Effective, Economical AND Imperative
Psychedelic medicine is both extremely efficacious and highly cost-effective. It is also an absolute necessity to RESCUE the economy.
Novamind Signs LOI to Acquire Two Mental Health Clinics in Arizona
Novamind announces an LOI to add two Arizona mental health clinics to its treatment network.
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
Cybin Inc reports its fiscal Q2 results for 2021. Advanced several drug development candidates and received a Schedule I manufacturing license. Cash and equivalents of CAD$75.2 million as of September 30, 2021.
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
MindMed announces its Q3 2021 results. Continued progress on R&D and pipeline development. Cash and equivalents of $178.6 million.
12Media34!
atai Life Sciences reports its Q3 2021 financial results. Continued progress across 11 therapeutic research programs. Cash and equivalents of $430.3 million as of September 30, 2021.
Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
Novamind Secures Insurance Coverage for Ketamine from Four Major Payors
Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
